Our Mission:

“We aspire to be the most respected and valued biotech in India, exemplified through a pipeline of compounds in clinical development addressing critical needs in Oncology, Inflammatory and Anti-infectives disease areas” 

In order to realize this Mission, Aurigene has pioneered a unique model of Drug Discovery collaborations with large-pharmaceutical, mid-pharmaceutical companies and Biotech companies — leveraging mutual strengths, sharing expertise and risks, and working on creative Collaboration, Licensing and Option arrangements customized for each situation.

Established in 2002 as one of India’s first biotechs, Aurigene has become a strategic partner for its customers, focused around several themes on which the partnerships have been built: Therapeutic area, target pathway or business strategy.

For its proprietary portfolio, Aurigene has specialized in the areas of Immune modulation for oncology (PD-1 and other targets in the Immune checkpoint pathway) using peptide & peptidomimetic (small molecule) approaches, Epigenetics and opportunistically, other targets for precision oncology medicine and ant-infectives.